-
Jeffrey R Huth,
Chang Park,
Andrew M Petros,
Aaron R Kunzer,
Michael D Wendt,
Xilu Wang,
Christopher L Lynch,
Jamey C Mack, Kerry M Swift,
Russell A Judge, [......],
Stephen K Tahir,
Edward D Matayoshi,
Sarah A Dorwin,
Uri S Ladror,
Jean M Severin,
Karl A Walter,
Diane M Bartley,
Stephen W Fesik,
Steven W Elmore,
Philip J Hajduk
[show abstract]
[hide abstract]
ABSTRACT: The molecular chaperone HSP90 has been shown to facilitate cancer cell survival by stabilizing key proteins responsible for a malignant phenotype. We report here the results of parallel fragment-based drug design approaches in the design of novel HSP90 inhibitors. Initial aminopyrimidine leads were elaborated using high-throughput organic synthesis to yield nanomolar inhibitors of the enzyme. Second site leads were also identified which bound to HSP90 in two distinct conformations, an 'open' and 'closed' form. Intriguingly, linked fragment approaches targeting both of these conformations were successful in producing novel, micromolar inhibitors. Overall, this study shows that, with only a few fragment hits, multiple lead series can be generated for HSP90 due to the inherent flexibility of the active site. Thus, ample opportunities exist to use these lead series in the development of clinically useful HSP90 inhibitors for the treatment of cancers.
Chemical Biology & Drug Design 08/2007; 70(1):1-12. · 2.28 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Fluorescence methods are commonly used in pharmaceutical drug discovery to assay the binding of drug-like compounds to signaling proteins and other bio-particles. For binding studies of non-fluorescent compounds, a competitive format may be used in which the binding of the compound results in displacement of another fluorescently labeled ligand. Highly-sensitive measurements within nano-liter sized open probe volumes can be accomplished using a confocal epi-illumination geometry and thus key tools for such drug-binding studies include fluorescence correlation spectroscopy (FCS) and its related techniques. This paper reviews the general protocol for application of FCS to biomolecular compound-binding assays and it focuses on methods for the reduction of experimental photon count data to obtain the normalized autocorrelation function (ACF), on theoretical models of the ACF, and on statistical and systematic errors in the experimental ACF. Results from a detailed Monte Carlo simulation of FCS, which are useful for testing theoretical models and validating short-duration assay capabilities, are discussed. An illustrative example is presented on the use of FCS to assay binding of Alexa-488-labeled Bak peptide with Bcl-x(L), which is an intracellular protein that acts to protect against programmed cell death.
Current Pharmaceutical Biotechnology 01/2004; 4(6):451-62. · 2.81 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Fluorescence correlation spectroscopy (FCS) enables direct observation of the translational diffusion of single fluorescent molecules in solution. When fluorescent hapten binds to antibody, analysis of FCS data yields the fractional amounts of free and bound hapten, allowing determination of the equilibrium binding constant. Equilibrium dissociation constants of anti-digoxin antibodies and corresponding fluorescein-labeled digoxigenin obtained by FCS and fluorescence polarization measurements are identical. It is also possible to follow a competitive displacement of the tracer from the antibody by unlabeled hapten using FCS in an immunoassay format. The fluorescence polarization immunoassay for vancomycin detection was used to test the FCS approach. Fitting of the FCS data for the molar fractions of free and bound fluorescein-labeled vancomycin yielded a calibration curve which could serve for determination of the vancomycin concentration in biological samples.
Analytical Biochemistry 09/2002; 307(1):84-91. · 3.00 Impact Factor
-
Kent D Stewart,
Kevin Steffy,
Kevin Harris,
John E Harlan,
Vincent S Stoll,
Jeffrey R Huth,
Karl A Walter,
Emily Gramling-Evans,
Renaldo R Mendoza,
Jean M Severin,
Paul L Richardson,
Leo W Barrett,
Edmund D Matayoshi, Kerry M Swift,
Stephen F Betz,
Steve W Muchmore,
Dale J Kempf,
Akhter Molla
[show abstract]
[hide abstract]
ABSTRACT: Two new proteins of approximately 70 amino acids in length, corresponding to an unnaturally-linked N- and C-helix of the ectodomain of the gp41 protein from the human immunodeficiency virus (HIV) type 1, were designed and characterized. A designed tripeptide links the C-terminus of the C-helix with the N-terminus of the N-helix in a circular permutation so that the C-helix precedes the N-helix in sequence. In addition to the artificial peptide linkage, the C-helix is truncated at its N-terminus to expose a region of the N-helix known as the "Trp-Trp-Ile" binding pocket. Sedimentation, crystallographic, and nuclear magnetic resonance studies confirmed that the protein had the desired trimeric structure with an unoccupied binding site. Spectroscopic and centrifugation studies demonstrated that the engineered protein had ligand binding characteristics similar to previously reported constructs. Unlike previous constructs which expose additional, shallow, non-conserved, and undesired binding pockets, only the single deep and conserved Trp-Trp-Ile pocket is exposed in the proteins of this study. This engineered version of gp41 protein will be potentially useful in research programs aimed at discovery of new drugs for therapy of HIV-infection in humans.
Journal of Computer-Aided Molecular Design 21(1-3):121-30. · 3.39 Impact Factor
